BACKGROUND: Disease stage is the most important prognostic parameter in allogeneic hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia, but other factors such as donor/host histocompatibility and gender combination, recipient age, performance status and comorbidities need to be considered. Several scoring systems are available to predict outcome in HCT recipients; however, their prognostic relevance in acute lymphoblastic leukemia is not well defined. DESIGN AND METHODS: In the present study we evaluated a modified EBMT risk score (mEBMT) and the HCT-specific comorbidity index (HCT-CI) in 151 adult acute lymphoblastic leukemia patients who received allogeneic HCT from 1995 until 2007 at our center. RESULTS: Disease status was first complete remission (CR1) (47%), CR>1 (21%) or no CR (32%). Overall survival (OS) at one, two and five years was 62%, 51% and 40% and non-relapse mortality (NRM) was 21%, 24% and 32%. Median mEBMT was 3 (0-6). Higher mEBMT was associated with inferior OS (hazard ratio per score unit (HR): 1.50, P<0.001), higher NRM (HR: 1.36, P=0.042) and higher relapse mortality (HR: 1.68, P<0.001). Disease stage was the predominant prognostic factor in this score. Comorbidities were present in 71% of patients with mild hepatic disease (29%), moderate pulmonary disease (28%) and infections (23%) being the most common. Median HCT-CI was 1 (0-9). In univariate analysis a trend for inferior OS (HR: 1.08, P=0.20) and higher NRM (HR: 1.14, P=0.11) with increasing HCT-CI was observed but the level of significance was not reached. In additional analyses we found that reduced Karnofsky Performance Status (KPS) was associated with inferior OS (HR: 1.34, P=0.023) and higher relapse mortality (HR: 1.71, P=0.001) when analyzed univariately. However, KPS was associated with disease stage and significance was lost in multivariate analysis. CONCLUSIONS: The mEBMT was prognostic in our patient cohort with predominant influence of disease stage, whereas a trend but no significant prognostic value was observed for the HCT-CI.
BACKGROUND: Disease stage is the most important prognostic parameter in allogeneic hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia, but other factors such as donor/host histocompatibility and gender combination, recipient age, performance status and comorbidities need to be considered. Several scoring systems are available to predict outcome in HCT recipients; however, their prognostic relevance in acute lymphoblastic leukemia is not well defined. DESIGN AND METHODS: In the present study we evaluated a modified EBMT risk score (mEBMT) and the HCT-specific comorbidity index (HCT-CI) in 151 adult acute lymphoblastic leukemiapatients who received allogeneic HCT from 1995 until 2007 at our center. RESULTS: Disease status was first complete remission (CR1) (47%), CR>1 (21%) or no CR (32%). Overall survival (OS) at one, two and five years was 62%, 51% and 40% and non-relapse mortality (NRM) was 21%, 24% and 32%. Median mEBMT was 3 (0-6). Higher mEBMT was associated with inferior OS (hazard ratio per score unit (HR): 1.50, P<0.001), higher NRM (HR: 1.36, P=0.042) and higher relapse mortality (HR: 1.68, P<0.001). Disease stage was the predominant prognostic factor in this score. Comorbidities were present in 71% of patients with mild hepatic disease (29%), moderate pulmonary disease (28%) and infections (23%) being the most common. Median HCT-CI was 1 (0-9). In univariate analysis a trend for inferior OS (HR: 1.08, P=0.20) and higher NRM (HR: 1.14, P=0.11) with increasing HCT-CI was observed but the level of significance was not reached. In additional analyses we found that reduced Karnofsky Performance Status (KPS) was associated with inferior OS (HR: 1.34, P=0.023) and higher relapse mortality (HR: 1.71, P=0.001) when analyzed univariately. However, KPS was associated with disease stage and significance was lost in multivariate analysis. CONCLUSIONS: The mEBMT was prognostic in our patient cohort with predominant influence of disease stage, whereas a trend but no significant prognostic value was observed for the HCT-CI.
Authors: Frédéric Baron; Rainer Storb; Barry E Storer; Michael B Maris; Dietger Niederwieser; Judith A Shizuru; Thomas R Chauncey; Benedetto Bruno; Stephen J Forman; Peter A McSweeney; Richard T Maziarz; Michael A Pulsipher; Edward D Agura; James Wade; Mohamed Sorror; David G Maloney; Brenda M Sandmaier Journal: J Clin Oncol Date: 2006-08-08 Impact factor: 44.544
Authors: Andrew S Artz; Daniel A Pollyea; Masha Kocherginsky; Wendy Stock; Elizabeth Rich; Olatoyosi Odenike; Todd Zimmerman; Sonali Smith; Lucy Godley; Michael Thirman; Christopher Daugherty; Martine Extermann; Richard Larson; Koen van Besien Journal: Biol Blood Marrow Transplant Date: 2006-09 Impact factor: 5.742
Authors: Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer Journal: Blood Date: 2005-06-30 Impact factor: 22.113
Authors: Zi Yi Lim; Aloysius Y L Ho; Wendy Ingram; Michelle Kenyon; Laurence Pearce; Barbara Czepulkowski; Stephen Devereux; Rafael F Duarte; Antonio Pagliuca; Ghulam J Mufti Journal: Br J Haematol Date: 2006-08-25 Impact factor: 6.998
Authors: F Frassoni; M Labopin; E Gluckman; H G Prentice; J P Vernant; F Zwaan; A Granena; G Gahrton; T De Witte; A Gratwohl; J Reiffers; N C Gorin Journal: Bone Marrow Transplant Date: 1996-01 Impact factor: 5.483
Authors: A Gratwohl; J Hermans; J M Goldman; W Arcese; E Carreras; A Devergie; F Frassoni; G Gahrton; H J Kolb; D Niederwieser; T Ruutu; J P Vernant; T de Witte; J Apperley Journal: Lancet Date: 1998-10-03 Impact factor: 79.321
Authors: Haesook T Kim; Mei-Jie Zhang; Ann E Woolfrey; Andrew St Martin; Junfang Chen; Wael Saber; Miguel-Angel Perales; Philippe Armand; Mary Eapen Journal: Haematologica Date: 2016-06-27 Impact factor: 9.941
Authors: Mahmoud ElSawy; Barry E Storer; Michael A Pulsipher; Richard T Maziarz; Smita Bhatia; Michael B Maris; Karen L Syrjala; Paul J Martin; David G Maloney; Brenda M Sandmaier; Rainer Storb; Mohamed L Sorror Journal: Br J Haematol Date: 2015-05-05 Impact factor: 6.998
Authors: Mohamed L Sorror; Brent R Logan; Xiaochun Zhu; J Douglas Rizzo; Kenneth R Cooke; Philip L McCarthy; Vincent T Ho; Mary M Horowitz; Marcelo C Pasquini Journal: Biol Blood Marrow Transplant Date: 2015-04-07 Impact factor: 5.742
Authors: J Versluis; M Labopin; D Niederwieser; G Socie; R F Schlenk; N Milpied; A Nagler; D Blaise; V Rocha; J J Cornelissen; M Mohty Journal: Leukemia Date: 2014-05-20 Impact factor: 11.528